The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.
Rodriguez-Sevilla JJ, Adema V, Chien KS, Loghavi S, Ma F, Yang H, Montalban-Bravo G, Huang X, Calvo X, Joseph J, Bodden K, Garcia-Manero G, Colla S.
Rodriguez-Sevilla JJ, et al. Among authors: garcia manero g.
Nat Commun. 2024 Nov 13;15(1):9840. doi: 10.1038/s41467-024-54290-2.
Nat Commun. 2024.
PMID: 39537648
Free PMC article.
Clinical Trial.